Telehealth GLP-1 Scams Persist Despite Government Settlement
Telehealth GLP-1 Scams Persist Despite Government Settlement
A Wired investigation has uncovered that customers are continuing to report fraudulent practices when purchasing compounded GLP-1 drugs—popular weight-loss and diabetes medications—through a telehealth network, despite the company having previously paid $5 million to settle related complaints with the US government.
The reports highlight ongoing issues with the telehealth platform, which connects patients with providers who prescribe compounded versions of drugs like Ozempic and Wegovy. Compounded medications are custom-made formulations that are not FDA-approved in the same way as brand-name versions.
Customers have described experiences ranging from unauthorized charges to receiving medications that did not match what was prescribed. The persistence of these complaints suggests that the earlier settlement did not fully resolve the underlying issues with the company's practices.
This case underscores the risks associated with purchasing prescription medications through less-regulated telehealth channels, particularly for high-demand drugs like GLP-1 agonists that have seen widespread popularity for weight management.
Consumers are advised to verify the legitimacy of telehealth providers, ensure prescriptions come from licensed healthcare professionals, and report suspicious activity to appropriate regulatory bodies.